Provided by Tiger Fintech (Singapore) Pte. Ltd.

Arbutus Biopharma

3.57
+0.01500.42%
Volume:615.47K
Turnover:2.20M
Market Cap:682.63M
PE:-9.38
High:3.62
Open:3.56
Low:3.51
Close:3.55
Loading ...

Arbutus and Barinthus announce new data from IM-PROVE II trial

TIPRANKS
·
16 Nov 2024

Arbutus and Barinthus Bio Announce New Data From the IM-Prove Ii Trial Showing That the Addition of Nivolumab Increased Rates of Hbsag Loss in People With Chronic Hepatitis B

THOMSON REUTERS
·
16 Nov 2024

Arbutus Biopharma Price Target Maintained With a $5.00/Share by HC Wainwright & Co.

Dow Jones
·
07 Nov 2024

Promising Potential of Arbutus Biopharma’s Imdusiran in Achieving Functional Cure for Hepatitis B: Ed Arce’s Buy Rating

TIPRANKS
·
07 Nov 2024

Arbutus Biopharma Corp (ABUS) Q3 2024 Earnings Call Highlights: Promising Clinical Trials and ...

GuruFocus.com
·
07 Nov 2024

Q3 2024 Arbutus Biopharma Corp Earnings Call

Thomson Reuters StreetEvents
·
07 Nov 2024

Arbutus Biopharma Is Maintained at Buy by Chardan Capital

Dow Jones
·
07 Nov 2024

Promising Developments in Arbutus Biopharma’s Pipeline Lead to Buy Rating and Increased Price Target

TIPRANKS
·
07 Nov 2024

Arbutus Biopharma price target raised to $4.50 from $4 at Chardan

TIPRANKS
·
07 Nov 2024

BRIEF-Arbutus Biopharma files for mixed shelf of up to $300 mln

Reuters
·
07 Nov 2024

Arbutus Biopharma Corp Files for Mixed Shelf of up to $300 Mln - SEC Filing

THOMSON REUTERS
·
07 Nov 2024

Arbutus Biopharma’s Promising Clinical Developments and Strong Financial Position Justify Buy Rating

TIPRANKS
·
07 Nov 2024

Stock Track | Arbutus Biopharma Shares Slide Despite Positive Drug Trial Data

Stock Track
·
06 Nov 2024

Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates

Zacks
·
06 Nov 2024

Arbutus Biopharma Reports Promising Clinical Trial Results

TIPRANKS
·
06 Nov 2024

As Of September 30, 2024, Arbutus Had Cash, Cash Equivalents And Investments In Marketable Securities Of $130.8M Expected To Provide Cash Runway Into Q4 Of 2026

Benzinga
·
06 Nov 2024

Arbutus Biopharma Q3 2024 GAAP EPS $(0.10) Misses $(0.09) Estimate, Sales $1.34M Miss $1.86M Estimate

Benzinga
·
06 Nov 2024

Arbutus: Q3 Earnings Snapshot

Associated Press Finance
·
06 Nov 2024

Arbutus Biopharma Corp: Qtrly Loss per Shr $0.10

THOMSON REUTERS
·
06 Nov 2024

Arbutus Biopharma Corp: Cash Runway Into Q4 of 2026

THOMSON REUTERS
·
06 Nov 2024